These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 29909917)
1. Off the shelf T cell therapies for hematologic malignancies. McCreedy BJ; Senyukov VV; Nguyen KT Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
3. [Development of allogeneic CAR T-cells]. Alcazer V; Depil S Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810 [TBL] [Abstract][Full Text] [Related]
4. Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting. Kang Y; Li C; Mei H J Hematol Oncol; 2024 May; 17(1):29. PubMed ID: 38711046 [TBL] [Abstract][Full Text] [Related]
5. Toxicities associated with immunotherapies for hematologic malignancies. Leick MB; Maus MV Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916 [TBL] [Abstract][Full Text] [Related]
6. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]
7. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
8. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708 [TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies. Cooper ML; DiPersio JF Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968 [TBL] [Abstract][Full Text] [Related]
10. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives]. Nguyen S; Lacan C; Roos-Weil D Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811 [TBL] [Abstract][Full Text] [Related]
11. Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy. Bohineust A; Tourret M; Derivry L; Caillat-Zucman S Bull Cancer; 2021 Oct; 108(10S):S92-S95. PubMed ID: 34920812 [TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry? Salmikangas P; Kinsella N; Chamberlain P Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
14. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Wang W; Jiang J; Wu C Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy to get on point with base editing. Harbottle JA Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616 [TBL] [Abstract][Full Text] [Related]
16. Advances in CAR-T-cell therapy in T-cell malignancies. Zheng R; Zhu X; Xiao Y J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099 [TBL] [Abstract][Full Text] [Related]
17. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. Fleischer LC; Spencer HT; Raikar SS J Hematol Oncol; 2019 Dec; 12(1):141. PubMed ID: 31884955 [TBL] [Abstract][Full Text] [Related]